【摘要】 目的 探讨柔肝化纤解毒方辅助治疗对原发性肝癌患者经导管动脉栓塞化疗（TACE）术后中医证候及肝功能的影响。方法 根据TACE术后治疗方法的不同将100例原发性肝癌患者分为对照组和观察组，每组50例，对照组患者接受常规西药治疗，观察组患者在对照组的基础上接受柔肝化纤解毒方辅助治疗。比较两组患者的中医证候积分、术后综合征消失时间、肝功能指标[丙氨酸转氨酶（ALT）、天冬氨酸转氨酶（AST）、总胆红素（TBIL）]及不良反应发生率。结果 治疗后，两组患者的各中医证候（肋痛、胸闷善太息、痞块、纳呆）积分均低于本组治疗前，且观察组患者的各中医证候积分均低于对照组，差异均有统计学意义（P﹤0.05）。观察组患者术后肝区疼痛、发热、恶心呕吐、便秘消失时间均明显短于对照组，差异均有统计学意义（P﹤0.01）。治疗后，两组患者的ALT、AST、TBIL水平均低于本组治疗前，且观察组患者的ALT、AST、TBIL水平均低于对照组，差异均有统计学意义（P﹤0.05）。两组患者的不良反应总发生率比较，差异无统计学意义（P﹥0.05）。结论 针对接受TACE手术的原发性肝癌患者，术后采用柔肝化纤解毒方辅助治疗不仅能够改善中医证候，加快患者术后综合征消失，还能够提高其肝功能，且安全性较高。更多还原

【Abstract】 Objective To investigate the effect of rougan huaxian jiedu prescription adjuvant therapy on traditional Chinese medicine(TCM) syndrome and liver function in patients with primary liver cancer after transcatheter arterial chemoembolization(TACE). Method A total of 100 patients with primary liver cancer were divided into the control group(n=50, treated with conventional Western medicine) and observation group(n=50, treated with additional rougan huaxian jiedu prescription based on treatment in control group) according to different treatment methods after TACE. TCM syndrome scores, postoperative syndrome disappearance time, liver function [alanine aminotransferase(ALT), aspartate aminotransferase(AST) and total bilirubin(TBIL)], and adverse reactions were compared between the two groups. Result After treatment, the TCM syndrome(rib pain, chest tightness and frequent sigh, lump in the abdomen, and anorexia)scores in both groups were lower than those before treatment, with lower scores in the observation group than those in the control group(P<0.05). The postoperative syndrome(pain in the hepatic region, fever, nausea and vomiting, and constipation) disappearance time in the observation group were significantly shorter than those in the control group(P<0.01). The levels of ALT, AST and TBIL in both groups decreased after treatment, with lower levels in the observation group than those in the control group(P<0.05). There was no significant difference for the total incidence of adverse reactions between the two groups(P>0.05). Conclusion The adjuvant therapy of rougan huaxian jiedu presciption in the treatment of primary liver cancer after TACE can improve the TCM syndrome, promote the disappearance of postoperative syndrome, and improve lung function with superior safety.更多还原